Blog

The Alzheimer's Association reveals that PET represented just 0.7% of AD diagnostic tests — and explains why that number is about to change dramatically with new disease-modifying therapies.

The EMA's CHMP is accompanying donanemab (Kisunla) through its European regulatory process — a milestone that brings new hope for early Alzheimer's treatment and raises critical questions about diagnostic readiness.

I recently had the unique opportunity to join a bio-entrepreneurs podcast and share the story behind PraanaTech — our technology, our mission, and why accessible early diagnosis matters so much.

Why modularity and reconfigurability in PET open the door to new clinical uses and to bringing molecular imaging to more patients.

Requirements, traceability, verification, and validation: what it means to build hardware and software for medical devices in certifiable environments.

How time of flight (TOF) in PET improves contrast and effective resolution, and what it implies for detectors, electronics, and data acquisition.

MRI shows structure; PET reveals biology. For Alzheimer's and other neurodegenerative diseases, understanding why PET is indispensable — not redundant — is key to building a complete diagnostic picture.

Our first interview as a company — a milestone that gave us the chance to share publicly, for the first time, the technology and mission behind PraanaTech.

Behind every Alzheimer's statistic is a friend, a family member, a neighbor. Understanding the scale of this disease — and why early diagnosis matters — starts with seeing the people it touches.

Representing PraanaTech at the AD/PD 2024 conference, where the opening session made clear we are entering a new era for Alzheimer's — and where I saw just how urgent the challenge of accessible imaging has become.

The Alzheimer's Association is preparing for the widespread use of amyloid and tau PET — and as a member of their business consortium, PraanaTech is proud to be part of that effort.

We are thrilled to announce that PraanaTech has been selected for the RIoT accelerator program — a milestone that validates our technology and accelerates our path to making early Alzheimer's diagnosis accessible.

The dream that brought PraanaTech to life — making early, accurate Alzheimer's diagnosis accessible to everyone — is becoming a reality. We are ready.

PraanaTech presented at the JPM/Biotech Showcase 2024 in San Francisco — one of the most important stages in the global biotech calendar — bringing our vision for accessible Alzheimer's diagnostics to the world's leading investors and innovators.